IcoSema weekly injection aims for a first European launch in Italy

Italian diabetes specialists want the IcoSema weekly injection, which pairs insulin icodec with semaglutide in one shot, offered in Italy before any other European country. The push follows a change to its EU indication backed by the EMA's medicines committee and the publication of the COMBINE 4 trial in The Lancet Diabetes & Endocrinology, Il Sole 24 Ore reported on 26 October. The paper's headline says the product is now available, but its text describes Italy as a possible first, and no Italian price, reimbursement decision or launch date was reported.

What the CHMP changed for Kyinsu

Novo Nordisk sells the combination in the EU as Kyinsu, and it sits on our board as insulin icodec and semaglutide. According to Il Sole 24 Ore, the Committee for Medicinal Products for Human Use (CHMP) has amended the existing indication to read: "IcoSema is indicated for the treatment of adults with inadequately controlled type 2 diabetes mellitus, in addition to diet, exercise and oral antidiabetic medicines". As we set out in our story on the Kyinsu CHMP opinion, the earlier wording required adults to be poorly controlled on basal insulin or a GLP-1 drug first. In plain terms, the new text reaches people whose sugar is still too high on tablets alone, without a first step through a separate injection.

The status of the change matters for anyone tracking it. A CHMP opinion is a recommendation, and the European Commission issues the binding decision. The report does not say whether the Commission has already adopted the new wording, so we treat the wider label as recommended rather than final. Pricing and reimbursement are then settled country by country, and nothing in the report shows that Italian authorities have completed that step. On our board the molecule stays at the approved stage. What moves is the size of the population that could use the IcoSema weekly injection, because the label would no longer start at the point where daily or weekly injections have already failed. That is a commercial change as much as a clinical one, and it is still pending.

What the COMBINE 4 trial shows and leaves out

The newest evidence is the COMBINE 4 trial, which the report says was recently published in The Lancet Diabetes & Endocrinology and supports use in the population named in the new wording. Across the phase 3 program, the report states, the combination achieved better glucose control than basal insulin alone or semaglutide alone. Against a basal bolus regimen, which means a long acting insulin plus mealtime insulin shots, it was described as non inferior on efficacy rather than better. The report adds that people on the combination had a body weight advantage over the insulin regimens, and that clinically significant or severe hypoglycaemia was significantly reduced compared with the insulin comparators. Those are summary claims from a news account, not figures we could check against the journal.

Across the phase 3 program, the report states, the combination achieved better glucose control than basal insulin alone or semaglutide alone.

What the account leaves out is just as important for a careful reader. It gives no trial size, no named comparator for COMBINE 4, no treatment length and no HbA1c or weight figures, and we could not open the journal paper for this story, so we report none of those numbers. Salvatore De Cosmo, president of the Association of Diabetes Specialists (AMD), said "the results from the COMBINE 4 trial regarding patient satisfaction are encouraging, although the actual benefit in terms of long-term adherence will need to be confirmed in clinical practice". He also stressed that simpler treatment must come with personal care plans, patient education and proper monitoring. Satisfaction in a trial is a softer outcome than glucose control, and adherence over years is untested.

Why Italy wants to move first

The Italian case rests on scale and on delay. The report says more than 4 million adults in Italy live with diabetes, and more than 90 percent of them have type 2 disease. It also says about 26 percent of people with type 2 diabetes who need insulin put off starting it by more than two years, which can raise the risk of complications. Raffaella Buzzetti, president of the Italian Society of Diabetology (SID), framed the goal as making treatment "simpler, more sustainable and compatible with people's lives", not only more potent. One weekly shot in place of seven or more injections a week is the practical pitch, and the specialists quoted see it as a way to lower the barriers that keep people off insulin.

Italy has a track record here. The report says it was the first country in the world to make weekly insulin available, and it may now become the first in Europe to offer this combination. Francesco Giorgino, professor of endocrinology at the University of Bari Aldo Moro, said Italy could again help bring the treatment to patients quickly "whilst respecting the assessments of the competent authorities and the sustainability of the National Health Service". He added the hope that national health authorities would carefully consider the new formulation. That wording, as quoted in the newspaper's account, reads as an appeal for a decision rather than a report of one, which is why our signal stays flat until a reimbursement step is confirmed.

Where insulin icodec and semaglutide sits in the weekly race

The combination joins two weekly peptide signals. Insulin icodec is a basal insulin dosed once a week, and semaglutide is a GLP-1 receptor agonist that Novo Nordisk already sells in weekly and daily forms. Icodec on its own is moving too: our coverage of the pediatric approval for Awiqli described the FDA extending it to patients aged 10 and older with type 2 diabetes, while Eli Lilly works on a rival weekly insulin. Pairing the two drugs in one weekly shot is meant to keep the glucose effect of insulin while limiting the weight gain and low blood sugar that insulin alone can bring. The phase 3 summary above points that way, but the size of the effect needs the published data.

For the wider incretin field, the IcoSema weekly injection occupies a narrow lane. GLP-1 and dual agonist drugs such as semaglutide and tirzepatide compete for people with type 2 diabetes who do not yet need insulin, and daily pills are arriving, with the EMA committee recommending Lilly's orforglipron tablet for weight management and type 2 diabetes. The combination targets the point where insulin becomes necessary, and the wider label would let doctors reach that point earlier. Whether doctors use it that way depends on price, on reimbursement rules and on how the full COMBINE 4 figures compare with insulin and GLP-1 options already in use. None of those answers is in the current report, and Novo Nordisk has not been quoted on launch timing in Italy.

Conclusion

The IcoSema weekly injection now has a wider EU indication backed by the CHMP and a published COMBINE 4 trial, and Italian specialists want their country to offer it first. The gaps are real: the Commission step is not confirmed, Italy has announced no reimbursement decision, and the trial's figures were not in the report. Until those land, the move widens the possible market without changing what patients can get today. This story is research reporting, not medical advice.